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Abstract
Background Antithrombotic management in atrial fibrilla-
tion (AF) is currently based on clinical characteristics,
despite evidence of potential fine-tuning with transoeso-
phageal echocardiography (TEE). This open, randomised,
multicentre study addresses the hypothesis that a compre-
hensive strategy of TEE-based aspirin treatment in AF
patients is feasible and safe.
Methods Between 2005 and 2009, ten large hospitals in the
Netherlands enrolled AF patients with a moderate risk of
stroke. Patients without thrombogenic TEE characteristics
were randomised to aspirin or vitamin K antagonists
(VKA). The primary objective is to show that TEE-based
aspirin treatment is safe compared with VKA therapy. The
secondary objective tests feasibility of TEE as a tool to
detect echocardiographic features of high stroke risk. This
report compares randomised to non-randomised patients
and describes the feasibility of a TEE-based approach.
Results In total, 310 patients were included. Sixty-nine
patients were not randomised because of non-visualisation
(n=6) or TEE risk factors (n=63). Compared with non-
randomised patients, randomised patients (n=241) were
younger (65±11 vs. 69±9 years, p=0.004), had less
coronary artery disease (9 vs. 20%, p=0.018), previous
TIA (1.7 vs. 7.2%, p=0.029), AF during TEE (25 vs. 54%,
p<0.001), mitral incompetence (55 vs. 70%, p=0.038),
VKA use (69 vs. 82%, p=0.032), had a lower mean
CHADS2 score (1.2±0.6 vs. 1.6±1.0, p=0.004), and left
ventricular ejection fraction (59±8 vs. 56±8%, p=0.016).
Conclusions This study shows that a TEE-based approach
for fine-tuning stroke risk in AF patients with a moderate
risk for stroke is feasible. Follow-up data will address the
safety of this TEE-based approach.
Keywords Atrial fibrillation . Stroke risk . Antithrombotic
treatment
Introduction
Atrial fibrillation (AF) is an independent risk factor for stroke,
and patients with AF have a 5% annual risk for thromboem-
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bolic stroke, i.e. five times more than in patients without AF
[1, 2]. Therapy with vitamin K antagonists (VKA) reduces
the risk of thromboembolism dramatically: ischaemic stroke
by 67% and peripheral thromboembolism by 42% [3].
Alternatively, aspirin reduces the risk of ischaemic stroke
by 22%, but has a significantly lower risk of bleeding [4].
It is recommended to stratify the risk of ischaemic stroke in
patients with AF using straightforward clinical characteristics
[5]. However, many AF patients classified as having a high
or moderate risk for thromboembolism may actually be at
low risk, as was shown in the Stroke Prevention in Atrial
Fibrillation (SPAF) III study. In SPAF III, a subset of patients
with a very high risk of stroke underwent transoesophageal
echocardiography (TEE) [6]. Complex plaques in the aorta
and signs of atrial stasis (spontaneous echo contrast, low
peak emptying velocities and presence of thrombus in the
left atrium or left atrial appendage) appeared strongly
associated to a high risk of ischaemic stroke and peripheral
thromboeobolism [6–8]. Conversely, patients with a normal
TEE had an extremely low rate of thromboembolism despite
the fact that they had just used aspirin. Up till now no
prospective study on the clinical safety and feasibility of a
TEE-based risk assessment has been performed.
In the TEE-guIded randomized comparison of AspiRin
and VKA in patients with AF and an increased risk of
stroke (TIARA) pilot study we hypothesise that a compre-
hensive strategy of TEE-based aspirin treatment is safe and
feasible in AF patients who are eligible for vitamin K
antagonist therapy on the basis of conventional risk
assessment. Our primary objective is to show that—
compared with VKA therapy—TEE-based aspirin treatment
is safe with respect to a composite endpoint of major
cardiovascular and cerebrovascular events, in patients who
do not harbour predefined high-risk features on TEE. Our
secondary objective is to test the feasibility of TEE as a tool
to assess all four echocardiographic features of high stroke
risk, i.e. complex atheromatous plaques in the thoracic aorta
and signs of atrial stasis including dense spontaneous echo
contrast, thrombus or low blood flow velocity.
Here we report the study design and feasibility of TEE-
guided stroke risk assessment. In addition we compare the
baseline characteristics of randomised patients with those of
patients who were not randomised because of thrombogenic
TEE abnormalities.
Methods
Patients
Subjects were eligible for participation if they had docu-
mented paroxysmal or permanent AF, and a conventional
indication for VKA treatment (history of hypertension,
age >60 years with diabetes mellitus or coronary artery
disease, age >75 years). Subjects were excluded if they had an
indication for VKA treatment other than AF, secondary AF, a
contraindication for treatment with VKA or aspirin or a
contraindication for TEE [9]. Also patients with a presumed
very high risk of stroke and thromboembolism (previous
ischaemic stroke, transient ischaemic attack (TIA) or
systemic thromboembolism, heart failure or significant left
ventricular systolic dysfunction, mitral valve stenosis, hyper-
trophic cardiomyopathy) were not eligible. The Institutional
Review Boards of all participating hospitals approved the
study and written informed consent was obtained from all
patients. Since the risk of stroke in patients who suffered
from TIA but not from stroke is uncertain and its
mechanisms vary, the steering committee changed the
exclusion criteria of the study accepting also patients with
a history of TIA for screening. This protocol amendment was
implemented in March 2006.
Design
The TIARA pilot study was an open randomised, multicentre
trial in which a risk stratification based on TEE was examined
in AF patients with a moderate risk of stroke. The study was
performed in ten large hospitals in the Netherlands between
2005 and 2009. All centers are highly experienced in
echocardiography.Most patients were enrolled in the outpatient
clinic, but also hospitalised patients were included. The trial has
been registered under ClinicalTrials.gov # NTC 00224757.
Patients underwent a TEE and were randomly assigned
to aspirin or VKA treatment if TEE did not show high-risk
abnormalities. Patients assigned to aspirin received a once-
daily dose of 100 mg and patients assigned to VKA
received adjusted-dose acenocoumarol or phenprocoumon
(target INR 2.5 to 3.5). Obviously, patients with one or
more abnormalities on TEE were excluded from random-
isation and received adjusted-dose VKA and were followed
in the high-risk observational group. The Netherlands’
regional Thrombosis Service routinely checked the INR.
All patients were followed up for at least 1 year. Figure 1
depicts the flow chart of screening, randomisation and
follow-up of included patients in the TIARA pilot study.
Echocardiographic procedures
All TEEs were performed and interpreted by certified
cardiologists in a standard fashion, as recommended by the
American Society of Echocardiography [9]. All echocardio-
grams were acquired by commercially available equipment:
HP Sonos 5500 imaging system (Hewlett-Packard Co.,
Andover, MA) or Vingmed System V (General Electric
Company, Fairfield, Connecticut) equipped with a 5-MHz
omniplane probe for TEE.When in doubt, the echocardiograms
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could be sent to the echo core laboratory (Maastricht University
Medical Center) for review.
TEE was performed with a 5-MHz omniplane transduc-
er. The oropharynx was anaesthetised by use of topical
lidocaine spray and viscous lidocaine solution prior to
insertion of the probe. The left atrial appendage (LAA) was
imaged by placing the probe at the level of the mid-
oesophagus. The plane of the multiplane probe was
adjusted to achieve a short-axis view of the aortic valve
(45°); to obtain an optimal view of the left atrial appendage,
the shaft of the scope was rotated anticlockwise in 5 to 10°
increments from 0 to 180°. Multiple views of the LAAwere
then obtained; cine loops were acquired [10]. The imaging
plane and gain settings were adjusted for optimal visual-
isation of thrombi and spontaneous echo contrast (SEC) in
the left atrium (LA), LAA, right atrium (RA) and right
atrial appendage (RAA). For measurement of the blood
flow velocities in the LAA, the sample of the pulsed wave
Doppler was placed at the orifice of the LAA and the
profile of the velocities was recorded over at least five
cardiac cycles. A maximum velocity was then calculated by
averaging these five cardiac cycles [11]. In order to image
complex plaques, the thoracic aorta was carefully visualised
by retracting and rotating the probe.
Definition of high-risk echocardiographic features
The following definitions were used for echocardiographic
abnormalities. Spontaneous echo contrast was defined as a
persistent pattern of a slow swirling motion of intracavitary
echo density throughout the LA and LAA at normal gain
[6]. A thrombus was defined as an intracavitary echodense
mass with sharp edges, echogenicity different from adjacent
structures, some degree of mobility, and present in more
than one plane [12]. Low blood flow velocity was defined
as peak emptying velocity of less than 25 cm/s on TEE,
measured at the orifice of the LAA. Complex atheromatous
plaque was defined as a mobile, pedunculated or ulcerated
plaque, or plaque thickness ≥4 mm in the thoracic aorta [7].
Randomisation
Randomisation was performed by permuted block
design with stratification for each participating hospital.
Eligible patients were randomised to either treatment
with aspirin 100 mg once daily or treatment with adjusted-
dose VKA. In patients randomised to VKA, the INR was
checked by the regional Thrombosis Service on a routine
basis.
Follow-up
Patients visited the outpatient clinic at 3, 6 and 12 months
after randomisation and at the end of the study. All
patients were followed up for at least 1 year. If needed,
patients were seen between regular visits. At every visit,
symptoms and signs of the composites of the primary
endpoint were checked. Also INR values were collected.
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Fig. 1 Overview of the screening, randomisation and follow-up of the
TIARA pilot study. Eligible patients were planned for TEE to assess
presence or absence or echocardiographic features of high risk of
stroke i.e. signs of atrial stasis and complex aortic plaques. VKA
vitamin K antagonists, TEE transoesophageal echocardiography,
Positive TEE presence of at least one of the echocardiographic
features of high risk of stroke, Negative TEE absence of echocardio-
graphic features of high risk of stroke, QoL Quality of life scores
using SF-36, EuroQol 5-D, Minnesota and AFSS questionnaires
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TEE was not repeated on a regular basis in the
included patients. Within the study period it was
not expected that aortic plaque or left atrial low flow
states would develop if not present on the first
examination. A TEE was, however, repeated when
clinically indicated. If electrical cardioversion was
indicated, aspirin patients were temporarily switched
to VKA. One month after the shock, irrespective of the
rhythm, aspirin was reinstituted.
Quality of life questionnaires
The quality of life was studied using the EuroQol 6-D, the
Short Form (SF)-36 Health Survey questionnaire and the
Toronto Atrial Fibrillation Severity Scale (AFSS) at
inclusion and after 12 months of follow-up. SF-36
contained items to assess physical health and mental health,
AFSS secured AF-specific complaints. The quality of life
assessment was completed with a multidimensional index
that contains five subscales: general, physical, activity,
motivation and cognition.
Data collection
Data were collected using an electronic case report
form accessed at a secure Internet site. Data were
transferred through the Internet to the central database
in Maastricht. Data could be either entered online, or
offline with frequent data transfer. By using a valida-
tion plan, integrated in the data entry software, data
were continuously checked for missing or contradictory
entries and values out of the normal range. The study-
monitoring nurse performed additional edit checks. The
data analysis was done at the Maastricht University
Medical Center. Patient identification was registered in
the participating centres, and was not transferred to the
central database. Questionnaires for quality of life were
processed by the Center for Data and Information
Management (MEMIC), a subdivision of the department
of the Faculty of Health, Medicine and Life Sciences
(Maastricht University).
Endpoints
The primary endpoint was a composite of (1) stroke
including haemorrhagic strokes, (2) systemic embolism,
(3) major bleeding, (4) acute coronary syndrome (unstable
angina and myocardial infarction) and (5) all-cause
mortality.
The Central Independent Adjudication Committee
(CIAC) independently adjudicated all events using
definitions as mentioned below. In case of doubt the
members held a conference for an unanimous adjudi-
cation. Definitions of primary endpoints are described
in the Appendix.
Statistical analysis
Sample size calculation was driven by the primary
endpoint on safety, i.e. the composite endpoint. The
incidence of the composite safety endpoint with aspirin
treatment could be estimated from the available litera-
ture. In patients with a normal TEE, the estimated
yearly incidences of ischaemic stroke and systemic
thromboembolism, major bleeding, acute coronary syn-
drome and death with aspirin treatment were 1.1%,
0.7%, 0.8% and 1.8%, respectively. Therefore, the
estimated yearly incidence of the composite primary
endpoint was 4.4% with aspirin. With VKA treatment
(INR 2.0–3.0) the yearly incidences of ischaemic stroke
and systemic thromboembolism, major bleeding, acute
coronary syndrome and death were 1.0%, 1.7%, 1.0%
and 1.8%, respectively. As a result, the estimated yearly
incidence of the composite endpoint with VKA treat-
ment was 5.5%. With an estimated average follow-up
duration of 1.5 years, the estimated incidences of the
composite safety endpoint were 6.6% for the aspirin
group and 8.3% for the VKA group, respectively.
The primary safety objective of this pilot study is to
show that applying TEE-based aspirin prophylaxis does
not lead to unacceptable high frequency of the safety
endpoint. Inclusion of 300 patients (150 per random-
isation arm) would rule out an excess of 7% with a
power of 80% and a type I error of 5%. The difference
in incidence of the safety endpoint in the randomised
groups was calculated and described with an exact one-
sided 95% confidence interval. A Kaplan-Meier curve
will be used to visualise the occurrence of events over
time. Hazard ratios will be calculated using Cox
regression. Similar analyses will be done for the separate
components of the safety endpoint.
The secondary—feasibility—objective will be evaluated
by calculating the number of patients eligible for the TEE
approach in whom the TEE cannot be performed or does
not yield unequivocal information on echocardiographic
thromboembolism risk markers.
Data that are not normally distributed will be log-
transformed and presented as geometric means. Analyses
were done using the t-test for independent groups for
continuous variables and Fisher’s exact test for categorical
variables. SPSS was used for all statistical calculations.
Analyses will be done using the intention-to-treat principle,
that is, patients will be analysed in the group to which they
were randomly assigned, regardless of the treatment they
actually received. A P value less than 0.05 is considered
statistically significant. All tests are two-tailed.
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Results
Baseline characteristics
The inclusion in the TIARA pilot trial was slower than
expected and the follow-up period longer than foreseen. As
a consequence inclusion was stopped after 310 patients and
a projected mean follow-up duration of 1.6 years. Recruit-
ment was diminished predominantly due to refusal of
eligible patients to undergo a TEE examination because of
fear for the TEE. Analysis of the patient screening log
showed that 35% of patients eligible for participation in the
TIARA pilot study refused TEE for this reason.
In the group randomised to aspirin, three patients withdrew
their informed consent directly after randomisation. Therefore
they will be discarded from further analysis in respect to
follow-up. For the secondary (per protocol) analysis, patients
not meeting the inclusion (n=1 for VKA group, n=2 for
aspirin group), or exclusion criteria (n=3 for VKA group),
and patients randomised despite TEE abnormalities (n=1 for
VKA group), will be discarded from analysis.
We had included 310 patients by July 2008, of which
241 (78%) patients were randomised. In total, 69 patients
were not randomised on the basis of an abnormal TEE
showing either predefined echocardiographic markers of a
high stroke risk or another abnormality considered highly
thrombogenic. Summaries of clinical and echocardiograph-
ic data are expressed as means or frequencies with 95%
confidence intervals (CIs) (Table 1). Non-randomised
observational patients had a slightly higher CHADS2 score
due to on average higher age, higher prevalence of diabetes
mellitus and previous TIA. The prevalence of hypertension
was very high and similar in both groups. On the other
hand, the prevalence of TIA was low, while patients with
stroke and heart failure were excluded. Non-randomised
observational patients were more often in AF at the time of
TEE and had mitral incompetence of any grade more
frequently. They also more often used a vitamin K
antagonist at entry. Distribution of type of AF (paroxysmal
or permanent) did not differ among groups.
Feasibility of TEE-guided stroke risk assessment
Of all 310 patients planned for TEE, 69 were not eligible
for randomisation because of non-visualisation (n=5),
technical failure (n=1) or abnormal TEE (n=63) (Table 2).
At least one echocardiographic marker for thromboembo-
lism could not be visualised with certainty in five patients;
mostly due to incomplete imaging of the LAA and
therefore LAA flow velocities could not be measured
(n=4). In the remaining patient, the aorta could not be
visualised. In one patient, TEE could not be performed
because of technical reasons; the patient was not capable of
swallowing the probe and therefore none of the markers for
thromboembolism were visualised. Furthermore, 63 patients
had abnormalities on TEE, of which 60 patients (19.7%) had
at least one predefined risk marker on TEE. Thrombi were
detected in ten patients (3.3%), low LAA flow velocities were
seen in 33 patients (10.9%), spontaneous echo contrast in 22
patients (7.2%), and complex plaques in 13 patients (4.3%).
The majority had only one risk marker (n=49, Table 2); LAA
flow velocities, SEC, complex plaques and thrombi were
seen in 20, 11, 9 and 6 patients, respectively. In 13 patients,
two abnormalities were detected with TEE; seven patients
had low LAA flow velocities with SEC, three patients had a
thrombus with low LAA flow velocities, and three patients
had SEC with complex plaques. Only one patient had all
four markers of thromboembolism risk on TEE.
Surprisingly, other cardiac abnormalities were observed in
three patients who had no other risk markers for stroke; two
patients had Lambl’s excrescences on the aortic valve and one
patient had a myxoma in the left atrium. Lambl’s excrescences
are not considered to be a primary source of cardioembolism
in patients with sinus rhythm, but the importance in atrial
fibrillation remains uncertain [13]. These patients were
therefore not randomised. The patient with a myxoma
refused surgery, and therefore was not randomised because
of the need for permanent anticoagulation.
Thus, TEE could provide accurate information on
thromboembolic risk in 304 out of 310 patients (98.1%).
Discussion
The TIARA pilot study is a randomised comparison of aspirin
and vitamin K antagonists for stroke prevention in patients
with a moderate stroke risk who do not harbour predefined
high-risk features on TEE. It was constructed as a pilot study
to show feasibility and to prepare a larger study later on.
Considering the high number of equivocal TEE imaging
results (98.1% of patients) and the low number of technical
failures of TEE, we feel that a TEE-guided approach is
feasible in clinical practice. If our study shows that TEE-based
aspirin treatment is also safe, this may form the basis for a
large TEE-guided stroke risk assessment trial.
We found that in only six out of the 310 included
patients (1.9%) irrefutable information about the thrombo-
genicity could not be obtained by TEE. In one patient a
TEE could not be performed due to technical reasons, and
in the remaining five patients the left atrial appendage and
aorta could not be visualised accurately. This high technical
success rate may relate to the fact that all participating
centers in the TIARA pilot study were highly trained in
performing TEE. However, TEE is now well incorporated
in the daily practice of any cardiology clinic. We hence
believe that a TEE-based approach for fine-tuning stroke
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risk in AF patients with a moderate risk for stroke is
feasible, not only in this trial but also in real-life.
In patients using VKA before TEE, VKAwas not stopped
prior to performing TEE. Of note, VKA does not influence the
presence of SEC and LAA flow velocities, or complex plaques
since it does not alter the underlying haemodynamic mecha-
nism [14–16], nor aortic plaque anatomy and complexity [17],
respectively. On the other hand, continued VKA therapy may
have precluded finding thrombi on TEE. However, we
reasoned that the incidence of thrombi after stopping VKA in
patients randomised to aspirin would be low, especially since
high LAA flow velocities and absence of SEC virtually exclude
thrombus [15, 18]. In this respect, of all three echocardio-
graphic atrial thrombosis markers, LAA flow velocity
measurement is the most robust concerning sensitivity and
specificity for thrombosis risk [8, 19]. Therefore, to prevent
unjust randomisation as much as possible we used a higher than
usual cut off of LAA flow velocity of 25 cm/s. Notwithstanding
the above, temporary discontinuation of stable VKA treatment
for e.g. 4 weeks to assess stroke risk markers with TEE off
VKA may seem feasible since most patients eligible for the
Randomised patients Non-randomised
patients
(observational group)
p-value
n=241 n=69
Clinical characteristics
Age (years) 65±11 69±9 0.004
Male,% 66 61 0.479
Hypertension,% 90 86 0.388
Coronary artery disease,% 9 20 0.018
Diabetes,% 10 19 0.057
Transient ischaemic attack,% 1.7 7.2 0.029
CHADS2 score 1.2±0.6 1.6±1.0 <0.001
- Score 0,% 2.1 4.3
- Score 1,% 76.3 53.6
- Score ≥2,% 21.6 42.1
Time since 1st diagnosis AF (years) 4.9±9.0 4.6±6.1 0.754
Type of AF 0.320
- Paroxysmal,% 85 78
- Permanent,% 15 22
Body mass index (g/m2) 28±5 28±5 0.458
Systolic blood pressure (mmHg) 136±18 137±18 0.615
Diastolic blood pressure (mmHg) 80±9 82±10 0.288
Antithrombotic drug at
baseline,%
99 99 0.637
- VKA at baseline,% 69 82 0.032
- Aspirin at baseline,% 32 18 0.023
Echocardiography
AF during TEE,% 25 54 <0.001
Left atrial diameter (mm) 41±11 42±12 0.389
Left ventricular ejection fraction (%) 59±8 56±8 0.016
Left ventricular mass (g/m2) 124±83 130±102 0.571
End-diastolic septum width (mm) 9.6±2.6 10.1±3.2 0.204
End-diastolic posterior wall width (mm) 9.1±2.4 9.5±2.6 0.211
Mitral incompetence,% 55 70 0.038
Table 1 Characteristics of rand-
omised and non-randomised
patients
Data are expressed as mean ±
SD unless otherwise specified
AF atrial fibrillation, VKA vita-
min K antagonists, TEE trans-
oesophageal echocardiography
Table 2 Reasons for non-randomisation
n=69
Technical reasons/patient refusal 1
At least one TEE risk factor not clearly visible 5
At least one TEE risk factor present 63
- 1 TEE abnormality 49
- 2 TEE abnormalities 13
- 3 TEE abnormalities 0
- 4 TEE abnormalities 1
TEE transoesophageal echocardiography
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TIARA approach have a relatively low stroke risk. Although
the stroke risk during 4 weeks of interrupted VKA is low, we
did not feel justified to do so, especially since the guidelines
advise keeping discontinuation of VKA (e.g. to perform
elective surgery) as short as possible.
The overall mean CHADS2 score was fairly low and
median CHADS2 score was only 1, mainly because we did
not consider patients with a previous stroke or heart failure.
In contrast, patients included in RACE [20] and AFFIRM
[21] were older and were presumably in a higher CHADS2
risk category mostly due to previous stroke and heart
failure, although hypertension was less frequent. Obviously,
the patients enrolled in the ACTIVE trial [22] and RELY
study [23] had higher CHADS2 scores because patients at
higher risk for thromboembolism were included, whereas
the TIARA pilot study intended to focus on patients with an
intermediate risk, i.e. a lower CHADS2 score.
Patients who were excluded from randomisation (non-
randomised observational group) because of TEE abnormal-
ities had, expectedly, a higher mean CHADS2 score than
randomised patients, mainly due to higher average age and
higher prevalence of diabetes. Nevertheless, the median
CHADS2 score is 1 in both randomised and non-randomised
groups. We can conclude that the average patient randomised
in the TIARA pilot study was the younger patient with well-
controlled hypertension and paroxysmal AF without other
risk factors of the CHADS2 risk score (i.e. heart failure,
previous stroke or TIA, diabetes, and older age). The
relatively high number of women included in the TIARA
study is remarkable, considering that women are generally
underrepresented in clinical trials.
In the non-randomised observational group, ten thrombi
were found (3.3% of patients); eight of these patients were on
VKA and two on aspirin. The number of thrombi as well as
stroke risk category in our study is comparable with several
recent studies showing prevalences of thrombi between 0.6%
and 3.6% [24–26]. Remarkably, also three patients (0.97%)
with a CHADS2 score of 0 had at least one TEE stroke risk
factor. Scherr et al. also report a prevalence of 0.3% thrombi
in patients with a CHADS2 score of 0 [25]. This underscores
our hypothesis that current risk stratification schemes—
which are based merely on clinical characteristics (such as
the CHADS2 score)—are unable to detect all patients with a
high risk of stroke with certainty. Surprisingly, three patients
had no thromboembolic markers but other abnormalities
with an indication for treatment with VKA. These patients
were asymptomatic beforehand, and they were subsequently
treated with VKA and followed in de observational group.
To our knowledge, this is the first study to show that routine
TEE yields unexpected findings in AF patients, leading to a
change of antithrombotic treatment.
Performing TEE in AF patients with a low to average
thromboembolism risk (CHADS2 score of 0 and 1) is useful
since it may enhance aspirin or no antithrombotic treatment
in some of these patients which may reduce avoidable
bleeding. In addition, in patients considered at low risk,
TEE may detect high-risk features warranting VKA
therapy, protecting these patients from unexpected strokes.
In this respect it is noteworthy that out of 310 patients with
an average CHADS2 risk score of 1, 63 patients had an
abnormal TEE (20.3%) necessitating continuation of or
switch to VKA therapy. Most noteworthy in this respect
were the three patients with a CHADS2 risk score of 0 who
appeared to have thrombogenic features on TEE.
Conclusions
In summary, the TIARA pilot study showed that a TEE-
based risk stratification in patients with atrial fibrillation
and a moderate risk for stroke is feasible. Decreasing the
threats and inconvenience of VKA is a desirable goal.
Identifying patients in whom VKA (or other antithrombotic
drugs) can be avoided may reduce bleeding and improve
quality of life without an increase in stroke complications
or costs of care. Application of a new echo-guided
antithrombotic strategy may help to reduce bleeding whilst
stroke prevention is maintained. If so, this study may
significantly change daily clinical practice of antithrom-
botic management of atrial fibrillation. These results may
form the basis for a larger multi-centre study.
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Principal Investigator
H.J.G.M. Crijns.
Steering Committee
H.J.G.M. Crijns (chairman), T. Dinh, L.H.B. Baur,
R. Pisters, O. Kamp, M.H. Prins, F.W.A. Verheugt.
Central Independent Adjudication Committee
C. de Zwaan (Department of Cardiology, chairman), M.
Limburg (Department of Neurology), H. ten Cate (Department
of Hematology), all Maastricht University Medical Center.
Participating centres and persons; number in parenthe-
ses indicates numbers of patients enrolled (all the
Netherlands)
Maastricht University Medical Center, Maastricht—T.
Dinh, H. Crijns, R. Pisters (133); Atrium Medical Center,
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Heerlen—L. Baur (121); VU Medical Center, Amsterdam—
O. Kamp (22); Rijnstate Hospital, Arnhem—J. Lindeboom
(7); VieCuri Medical Center, Venlo—F. Heesen (6); Radboud
University Nijmegen Medical Center, Nijmegen—J. Smeets
(4); Twenteborg Hospital, Almelo—H. Idzerda (5); Jeroen
Bosch Hospital, ‘s-Hertogenbosch—M. van Eck, H.
Haerkens-Arends (4); Diakonessenhuis, Meppel—K.
Thomas, H. Hoogslag (4); Amphia Hospital, Breda—M.
Baselier, M. Alings, T. Simmers (4), all the Netherlands.
Statistical analysis and data processing
T. Dinh (Study Coordinator), M.H. Prins (Head Depart-
ment of Clinical Epidemiology and Medical Technology
Assessment), Center for Data and Information Management
(MEMIC, Faculty of Health, Medicine and Life Sciences,
Maastricht University).
CardioResearch Maastricht University Medical Center
monitoring activities
I. Partouns-Hendriks, I. Ummels, L. Muis-Molin.
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Definitions of primary endpoint events
Stroke was subdivided into ischaemic stroke (including
lacunar stroke), haemorrhagic stroke or undefined stroke.
Each ischaemic stroke was further subdivided into cardio-
embolic, large-artery atherosclerotic stroke, lacunar stroke
(i.e. small-artery occlusion) or mixed/undefined/other.
Death was divided into cardiovascular death (due to
myocardial infarction, heart failure, documented stroke,
procedure-related death, due to other cardiovascular causes) or
non-cardiovascular death (related to cancer, primary infectious
disease, respiratory disease, suicide, accident or other).
Major bleeding was defined as clinically overt and (a)
associated with a fall in haemoglobin of 1.25 mmol/l or
more, or (b) leading to a transfusion of 2 or more units of
packed red blood cells or whole blood, or (c) bleeding in a
critical organ, i.e. intracranial, retroperitoneal, pericardial,
or (d) contributing to death. All other relevant bleeding was
classified as a non-major bleeding.
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